(Q37955304)

25 August 2017

title

Anti-angiogenic therapy: concept to clinic (English)

1 reference

25 August 2017

main subject

angiogenesis inhibitor

1 reference

Robin J Young

1

1 reference

25 August 2017

Malcolm W R Reed

series ordinal

2

1 reference

25 August 2017

publication date

1 February 2012

1 reference

25 August 2017

1 reference

25 August 2017

volume

19

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

115-125

1 reference

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

VHL and HIF signalling in renal cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Quo vadis with targeted drugs in the 21st century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

VEGF-A splicing: the key to anti-angiogenic therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Tumor-associated endothelial cells with cytogenetic abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Adaptation of skeletal muscle microvasculature to increased or decreased blood flow: role of shear stress, nitric oxide and vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Circulating endothelial cells as biomarkers in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

PET Imaging of Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Neuropilins: structure, function and role in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Neuropilins in physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1549-8719.2011.00147.X

10.1111/J.1549-8719.2011.00147.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference